Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
    • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   42312   clinical trials with a EudraCT protocol, of which   6968   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    1,453 result(s) found. Displaying page 28 of 73.
    «« First « Previous 24  25  26  27  28  29  30  31  32  Next» Last»»
    EudraCT Number: 2015-002117-30 Sponsor Protocol Number: 000010/BT Start Date*: 2016-02-16
    Sponsor Name:Bone Therapeutics S.A.
    Full Title: A Two-stage 6-month, Multicentre, Randomised, Double-blind, Controlled Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Patients with Symptomatic Knee Osteo...
    Medical condition: Symptomatic osteoarthritis of the knee with Kellgren-Lawrence grade II and III
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002530-50 Sponsor Protocol Number: EspeRare_RIM_001 Start Date*: 2015-11-04
    Sponsor Name:EspeRare
    Full Title: A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy.
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: ES (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002267-33 Sponsor Protocol Number: OCTO-089 Start Date*: 2017-06-13
    Sponsor Name:University of Oxford
    Full Title: A parallel group phase I/II marker lesion study to assess the safety, tolerability and efficacy of intravenous or intravesical pembrolizumab in intermediate risk recurrent non-muscle invasive bladd...
    Medical condition: Intermediate risk recurrent non-muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005056 Bladder neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001902-14 Sponsor Protocol Number: D5760C00001 Start Date*: 2017-11-06
    Sponsor Name:MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI4276 in Subjects with Select H...
    Medical condition: HER2 expressing Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066896 HER-2 positive gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 100000016800 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001382-32 Sponsor Protocol Number: BCT-521-201 Start Date*: 2019-11-26
    Sponsor Name:Beckley Canopy Therapeutics Ltd.
    Full Title: A Double-Blind, Randomized Phase 1/2 Study to Assess the Efficacy and Safety of BCT-521 Versus Placebo for Pain Associated With Cancer in Patients Already Receiving Standard of Care Treatment With ...
    Medical condition: Pain associated with cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058019 Cancer pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001699-12 Sponsor Protocol Number: 205019 Start Date*: 2019-08-27
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: An open-label, randomized three period cross-over relative bioavailability study to compare the pharmacokinetic parameters of a lower dose formulation of ambrisentan (GSK1325760) with marketed ambr...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003257-42 Sponsor Protocol Number: ACH-CYT-02 Start Date*: 2017-10-03
    Sponsor Name:Achieve Life Sciences Inc
    Full Title: Repeat-Dose Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers
    Medical condition: Smoking cessation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001023-23 Sponsor Protocol Number: CUTHIVAC002 Start Date*: 2015-08-24
    Sponsor Name:Imperial College London
    Full Title: A Phase I clinical trial to assess the safety and immunogenicity of HIV DNA-C CN54ENV immunisations administered via the Intramuscular and Intradermal methods with and without electroporation follo...
    Medical condition: HIV prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003741-26 Sponsor Protocol Number: GS-US-350-1604 Start Date*: 2016-11-17
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-5829 as a Single Agent and In Combination with Enzalutamide in Subjects with Metastatic Castrate...
    Medical condition: Metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000783-15 Sponsor Protocol Number: GP41341 Start Date*: 2019-05-07
    Sponsor Name:Genentech, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, TWO PART STUDY TO EXPLORE THE PERFORMANCE OF ENTRECTINIB PROTOTYPE MINI-TABLET FORMULATIONS AND THE EFFECT OF DRUG SUBSTANCE PARTICLE SIZE ON ENTRECTINIB BIOAVAILABILITY I...
    Medical condition: non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC), salivary gland cancers, papillary thyroid cancer, melanoma, and sarcomas
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023774 Large cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061934 Salivary gland cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003495-31 Sponsor Protocol Number: CCLL442X2201 Start Date*: 2017-12-14
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, Investigator-and patient-blind, placebo-controlled, parallel group first in human and proof of concept study to evaluate the safety, tolerability, and efficacy of CLL442 in patients w...
    Medical condition: Cutaneous Squamous Cell Carcinoma in situ (SCCis)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041834 Squamous cell carcinoma of skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003731-31 Sponsor Protocol Number: 2005 PK 02 Start Date*: 2005-03-09
    Sponsor Name:University Hospitals of Leiceter NHS Trust
    Full Title: Pharmacogenetics and metabolism of cyclophosphamide in paediatric non-Hodgkin’s Lymphoma
    Medical condition: non-Hodgkin's Lymphoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002801-22 Sponsor Protocol Number: X100 Start Date*: 2006-08-18
    Sponsor Name:The Royal Marsden NHSF Trust
    Full Title: Carboplatin Plus Xeloda Followed By Maintenance Xeloda (CARBOX)
    Medical condition: relapsed ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    6 10026662
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001506-29 Sponsor Protocol Number: ML 18729 Start Date*: 2005-10-10
    Sponsor Name:Group of Clinical Investigation in Radiotherapy Oncology (GICOR)
    Full Title: PHASE I/II TRIAL OF ERLOTINIB, RADIATIONTHERAPY, AND CISPLATIN IN PATIENTS WITH COMPLETE RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Ensayo Fase I/II de Erlotinib en combinación con radio...
    Medical condition: PATIENTS WITH COMPLETE RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
    Disease: Version SOC Term Classification Code Term Level
    PT 10014987 7.1
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002715-24 Sponsor Protocol Number: TARGET1 Start Date*: 2005-09-29
    Sponsor Name:Royal Marsden Hospital
    Full Title: TARGET Trial: A Phase I-II dose finding and early efficacy study of combination therapy with erlotinib (tarceva), gemcitabine, bevacizumab (avastin) and capecitabine in advanced pancreatic cancer.
    Medical condition: Advanced Pancreatic Cancer - either locally advanced disease not amenable to curative resection and metastatic disease.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033606 Pancreatic cancer non-resectable LLT
    9.1 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005978-51 Sponsor Protocol Number: TED6421 Start Date*: 2008-08-22
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Uncontrolled, multicenter, dose finding, safety and pharmacokinetic study of AVE1642, an anti-Insulin-like Growth Factor-1 Receptor (IGF-1R/ CD221) monoclonal antibody, administered as single agent...
    Medical condition: Advanced solid tumors
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003039-65 Sponsor Protocol Number: P30-120 Start Date*: 2008-06-03
    Sponsor Name:Alfacell Corporation
    Full Title: A phase I / II trial of intravenous Onconase(R) in subjects with non-small cell lung cancer
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029521 Non-small cell lung cancer stage IIIB LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004308-11 Sponsor Protocol Number: GTG002.07 Start Date*: 2010-01-11
    Sponsor Name:Genethon
    Full Title: PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME
    Medical condition: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by mutations in a single gene ,the Wiskott-Aldrich Syndrome Protein (WASP). WAS is characterised by micro-thrombocytopenia,...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10047992 Wiskott-Aldrich syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002328-40 Sponsor Protocol Number: HHSC/005 Start Date*: 2007-05-18
    Sponsor Name:Imperial College London
    Full Title: A phase I safety and tolerability study of infusing the autologous progeny of an adult CD34+ subset into patients with type I diabetes mellitus and a successful renal transplant.
    Medical condition: Diabetes mellitus type 1 and succesful renal transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012638 Diabetes with renal manifestations LLT
    9.1 10038533 Renal transplant LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000846-35 Sponsor Protocol Number: EFG100161 Start Date*: 2005-09-07
    Sponsor Name:GlaxoSmithKline
    Full Title: GlaxoSmithKline Study EGF100161 – An open-label, multicenter, 2 Part, Phase I/II dose escalation study of oral lapatinib in combination with docetaxel (Taxotere) plus trastuzumab (Herceptin) in sub...
    Medical condition: Metastatic Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 24  25  26  27  28  29  30  31  32  Next» Last»»
    Query did not match any studies.
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands     Legal notice
    EMA HMA